COMP <GO>
AXSM vs IONS // FREE CASH FLOW YIELD
Axsome Therapeutics Inc. (NASDAQ) VS. Ionis Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: AXSM 7
— IONS 3
▲ FREE CASH FLOW YIELD LEADER: AXSM
LAST: $136.01 (-5.83%) • MKT CAP: $7.12B
fcf-yield
-1.25%
LAST: $41.24 (-5.24%) • MKT CAP: $6.85B
fcf-yield
-4.34%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AXSM VS. IONS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AXSM | IONS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.90% | -20.90% | -1.00 | IONS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -1.25% | -4.34% | +3.09 | AXSM | /fcf-yield <GO> |
| Operating Margin | -26.10% | -40.40% | +14.30 | AXSM | /operating-margins <GO> |
| Net Profit Margin | -28.70% | -40.40% | +11.70 | AXSM | /net-margins <GO> |
| Revenue Growth (YoY) | 65.50% | 33.80% | +31.70 | AXSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.34 | 1.08 | +4.26 | AXSM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 5/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 20.5 | 36.2 | -15.70 | IONS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.09 | +0.06 | AXSM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.0x | 22.0x | +13.00 | IONS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.12B | $6.85B | $270.9M | AXSM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AXSM REV | IONS REV | AXSM GROSS % | IONS GROSS % | AXSM FCF | IONS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $638.5M | $943.7M | — | 98.3% | -$93.9M | -$320.0M |
| FY 2024 | $385.7M | $705.1M | — | 98.4% | -$128.7M | -$546.2M |
| FY 2023 | $270.6M | $787.6M | — | — | -$157.3M | -$343.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AXSM // BETA 1.15
IONS // BETA 1.09